TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female patients ≥ 20 years~2. ≥ 6 weeks since the last stroke~3. ≥ 2 points in the focal spasticity of wrist flexor and ≥ 1 points at least one of elbow flexor and finger flexor as measured on MAS(0 to 4)~4. Targeted one functional disability item (i.e., hygiene, dressing, pain, or cosmesis) with a rating of 2 or greater on DAS (0 to 3)~5. Informed consent has been obtained.~Exclusion Criteria:~1. Neuromuscular disorders such as Lambert-Eaton syndrome, myasthenia gravis, or amyotrophic lateral sclerosis~2. History(within 6 months of screening visit) or planned(during study period) treatment with phenol or alcohol injection or surgery in the target limb~3. History(within 6 months of screening visit) or planned(during study period) treatment with tendon lengthening in the target limb~4. Fixed joint/muscle contracture~5. Severe atrophy~6. Concurrent treatment with an intrathecal baclofen~7. History(within 3 months of screening visit) Planned(during study period) treatment with Botulinum Toxin~8. Known allergy or sensitivity to study medication or its components~9. Concurrent or planed Muscle relaxants and/or benzodiazepine medication~   * If patient has taken these medication stable from one month before screening and no treatment changes are not planned during the study, participation is allowed.~10. Current Physical, occupational, Splinting therapy~    * If these therapy regimens will be permitted if they has been stable in the one month before screening;no treatment and no changes are planned during the study.~11. Patient who are participating in other clinical trials at the screening~12. Females who are pregnant, breatfeeding,or planning a pregnancy during the study period, or female of childbearing potential, not using a reliable means of centraception.~13. Patients who are not eligible for this study at the discretion of the investigator.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Meditoxin® (Type: EXPERIMENTAL): Botulinum toxin type A
- Botox® (Type: ACTIVE_COMPARATOR): Botulinum Toxin type A

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Formoterol on the Counterregulatory Hormonal Response to Hypoglycemia in Type 1 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* type 1 diabetes (well controlled, 2-3 hypoglycemic episodes/wk)~* age 18-50~* BMI 18-30~Exclusion Criteria:~* pregnancy~* significant diabetes complications~* liver disease, cirrhosis~* cardiac disease~* neurological disorder~* autonomic neuropathy~* kidney disease~* lactose intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Type 1 Diabetics (Type: ACTIVE_COMPARATOR): The active group were participants with type 1 diabetes.
- Healthy Volunteers (Type: OTHER): The control group were participants without diabetes, matched by sex, age and BMI to the active comparator group.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of Vedolizumab for GvHD in Participants Undergoing Allogeneic HSCT

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Is undergoing matched or single-antigen mismatched unrelated-donor myeloablative transplant for the treatment of acute lymphoblastic leukemia (ALL) or acute myeloid leukemia (AML); Is less than or equal to (\<=) 60 years of age.~   For the cohort after RP2D~2. Is undergoing matched or single-antigen mismatched related or unrelated-donor transplant and receiving myeloablative conditioning or RIC for the treatment of hematologic malignancies or myeloproliferative neoplasms; Is less than or equal to (\<=) 75 years of age.~Exclusion Criteria:~1. Has received prior allogeneic transplants or who are planned to undergo umbilical cord blood transplant, receive ex vivo T-cell-depleted hematopoietic stem cells (HSCs), received any in vivo T-cell depleting antibodies, or non-myeloablative conditioning.~2. Has active cerebral/meningeal disease, active cytomegalovirus (CMV) colitis, or signs and symptoms of progressive multifocal leukoencephalopathy (PML) or any history of PML.~3. Is undergoing transplant for the treatment of nonmalignant hematological disorders (for example: aplastic anemia, sickle cell anemia, thalassemias, Fanconi anemia).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Vedolizumab 75 mg (Type: EXPERIMENTAL): Vedolizumab 75 mg, injection, intravenously once on Days -1, 13 and 42.
- Cohort 2: Vedolizumab 300 mg (Type: EXPERIMENTAL): Vedolizumab 300 mg, injection, intravenously once on Days -1, 13 and 42.
- Cohort 3: Vedolizumab Dose 1 (Type: EXPERIMENTAL): Vedolizumab first decided dose as determined from Cohort 1 or 2, injection, intravenously once on Days -1, 13 and 42.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: PDE-4 Inhibitor Roflumilast and GLP-1 Agonist Liraglutide in Polycystic Ovary Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years old to menopause~* polycystic ovary syndrome (NICHD criteria)~* BMI of 30 kg/m² or higher~Exclusion Criteria:~* depression~* type 1 or type 2 diabetes mellitus~* history of carcinoma~* history of pancreatitis~* Cushing's syndrome or congenital (non-classic) adrenal hyperplasia~* significant cardiovascular, kidney or hepatic disease~* the use of medications other than metformin known or suspected to affect reproductive or metabolic functions~* the use of statins, within 90 days prior to study entry

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- metformin (Type: ACTIVE_COMPARATOR): In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 2x1000 mg BID per os.
- liraglutide (Type: ACTIVE_COMPARATOR): In the liraglutide group liraglutide was initiated at a dose of 0,6mg sc once per day for one week and increased to 1,2mg sc one per day.
- roflumilast (Type: ACTIVE_COMPARATOR): In the roflumilast group roflumilast was initiated at a dose of 500 mg BID per os.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Induction of HO-1; a Therapeutic Approach to Reduce Ischaemia Reperfusion Injury (IRI) Following Deceased Donor Renal Transplantation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients receiving a cadaveric single kidney transplant~* patients on a standard immunosuppressive regime~Exclusion Criteria:~* patients on different immunosuppressives~* patients receiving 3rd or subsequent kidney transplant~* patients are fully anti-coagulated~* patients unable to take Heme Arginate~* patients unable to give informed consent~* patients on combined anti-platelet agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heme arginate (Normosang) (Type: ACTIVE_COMPARATOR): This arm will receive 2 doses of Heme Arginate (trade name Normosang); 1 dose prior to transplant and another on day 2. This is a product derived from human hemin and has been used for over 20 years in clinical practice with few side-effects.
- 0.9% saline (Type: PLACEBO_COMPARATOR): The saline will be given as an IV infusion in the same manner as the Heme Arginate (active comparator) infusion.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: MAST Trial: Multi-modal Analgesic Strategies in Trauma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients admitted to the trauma service who are 16 years and older.~Exclusion Criteria:~* pregnant~* prisoner~* patients placed in observation (i.e. not admitted to the hospital)

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Original MMPR - descending dose arm (Type: ACTIVE_COMPARATOR): Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g intravenously (IV)/per oral (PO) q6 hours in the first 48 hours, and Acetaminophen 1g PO q6 hours thereafter; 2. Ketorolac 30mg IV once and Celebrex 200mg PO q12 hours in the first 48 hours, and Naproxen 500mg PO q12 hours thereafter; 3. Tramadol 100mg PO q6 hours in the first 48 hours, and Tramadol 100mg PO q6 hours thereafter; 4. Pregabalin 100mg PO q8 hours in the first 48 hours, and Gabapentin 300mg PO q8 hours thereafter; 5. Lidocaine patch q12 hours in the first 48 hours, and Lidocaine patch q12 hours thereafter; and 6. Opioids (Regional anesthesia) in the first 48 hours, and Opioids and Regional anesthesia thereafter.
- MAST MMPR - escalating dose arm (Type: ACTIVE_COMPARATOR): Drugs are scheduled around the clock as follows: 1. Acetaminophen 1g PO q6 hours at admission and thereafter; 2. Ketorolac 30mg IV once and Naproxen 500mg PO q12 hours at admission and thereafter; 3. No drug; 4; Gabapentin 300mg PO q8 hours at admission and thereafter; 5. Lidocaine patch q12 hours at admission and thereafter; and 6. Tramadol and Opioids and Regional anesthesia at admission and thereafter.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~•Adult patients between the ages of 18 and 85 years (inclusive) with a diagnosis of IBS based on ROME III diagnostic criteria and meeting criteria for diagnosis of the constipation predominant subtype - IBS-C~Exclusion Criteria:~* Refusal or inability to sign informed consent for the trial~* Refusal or inability to complete daily Episodic (real-time) BM / RM calls, End of Day daily Calls, and/or complete electronic questionnaires~* BMI \> 35 or \< 18~* Women of child bearing potential who refuse to use an acceptable method of birth control for the duration of the trial~* Women who are pregnant or lactating~* Diagnosis of IBS-D or IBS-M~* Organic or obstructive disease of the small or large intestine~* Use of laxatives other than the study-supplied rescue medication (Dulcolax®, bisacodyl)~* Use of a prohibited concomitant medication within the time frame prior to screening outlined in the study protocol for that medication~* Unstable medical illness~* Bilirubin \> 3X ULN in the absence of a conjugation defect~* Any laboratory value \> 3X ULN unless discussed and approved by the study Medical Monitor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- 3.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 3.0 mg dosed daily for 12 weeks
- 6.0 mg plecanatide (Type: ACTIVE_COMPARATOR): Plecanatide 6.0 mg dosed daily for 12 weeks
- Matching placebo (Type: ACTIVE_COMPARATOR): Placebo dosed daily for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Combination of Chemotherapy and Gefitinib as First-line Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Age \>=18 years~3. Histologically documented, unresectable, inoperable, locally advanced, recurrent or metastatic Stage IV Non-Small Cell Lung Cancer (NSCLC)~4. A cytologic diagnosis is acceptable (i.e., FNA or pleural fluid cytology)~5. Measurable or non-measurable disease~6. Able to comply with study and follow-up procedures~Exclusion Criteria:~* Evidence of small cell, carcinoid, or mixed small cell/non-small cell histology~* Malignancies within 3 years except for adequately treated carcinoma in situ of -the cervix or basal or squamous cell skin cancer~* Symptomatic or untreated brain metastases~* Prior systemic chemotherapy for NSCLC~* Unstable systemic disease, including active infection, uncontrolled hypertension, unstable angina, congestive heart failure, or myocardial infarction within 6 months prior to Day 1, or serious cardiac arrhythmia requiring medication (patients with chronic atrial arrhythmia, i.e., atrial fibrillation or paroxysmal supraventricular tachycardia, are eligible)~* History of other diseases, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug or that might affect the interpretation of the results of the study or render the patient at high risk from treatment complications~* Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous (IV) alimentation, or prior surgical procedures affecting absorption~* Pregnancy or lactation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- chemotherapy group(B) (Type: EXPERIMENTAL): pemetrexed plus carboplatin pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) every 4 weeks for up to six cycles, then continued to receive pemetrexed(500 mg/m(2) on day 1) alone every 4 weeks
- combination therapy group(A) (Type: EXPERIMENTAL): pemetrexed (500 mg/m(2) on day 1) plus carboplatin (AUC 5 on day 1) combined with gefitinib (250 mg/day on days 5-21) and repeated every 4 weeks for up to six cycles,then continued to receive pemetrexed combined with gefitinib every 4 weeks.
- gefitinib group (group C) (Type: EXPERIMENTAL): received gefitinib( 250 mg/day)alone. All therapies of 3 groups were continued until progression or unacceptable toxicity or death

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Corneal Collagen Cross-Linking for Ectasia (CXL)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of ectasia after refractive surgery~* Documented ectasia on Pentacam or topography map~* BSCVA worse than 20/20~* Must complete all study visits~Exclusion Criteria:~* History of delayed wound healing~* History of corneal melt or corneal dystrophy

- Gender: ALL
- Minimum Age: 14 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Corneal Collagen Cross-linking (CXL) Treatment Group (Type: ACTIVE_COMPARATOR): riboflavin ophthalmic solution and UVA irradiation
- Control Group (Type: SHAM_COMPARATOR): riboflavin opthalmic solution without UVA irradiation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Subantimicrobial Dose Doxycycline for Moderate to Severe and Active Graves' Orbitopathy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of Graves' Orbitopathy~* Moderate-severe GO According to EUGOGO statements, patients with moderate-severe GO usually have any one or more of the following：moderate or severe soft tissue involvement, exophthalmos≥3mm above normal for race and gender, inconstant, or constant diplopia.~* Clinical activity score ≥ 3~* Being euthyroid for at least 1 month before the date of inclusion~* Must be able to swallow tablets~* Written informed consent is obtained~Exclusion Criteria:~* Mild Graves' Orbitopathy~* Sight-threatening Graves' Orbitopathy~* Clinical activity score \< 3~* Previous treatment for GO Oral steroids, intravenous steroids, radiotherapy~* Pregnant females as determined by positive (serum or urine) Human chorionic gonadotropin (hCG) test at screening or prior to dosing, or lactating females~* Uncontrolled diabetes or hypertension~* History of mental / psychiatric disorder~* Hepatic dysfunction (Albumin (Alb),Aspartate Transaminase (AST), Alanine Aminotransferase (ALT) and Alkaline phosphates levels must be within normal range for eligibility)~* Renal impairment (Urea and Creatinine levels must be within normal range)~* Doxycycline allergy or intolerance

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Tablets Doxycycline 50 mg PO per day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Efficacy and Safety of Pregabalin Against Frequent Muscle Cramp in Patients With Liver Cirrhosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: (should follow all conditions described below)~* Etiology : Liver cirrhosis patients of any etiology, whether viral or non-viral~* Occurrence of muscle cramp equal to or more than 2 times a week over the last month~Exclusion Criteria:~* Preexisting disease : Occlusive vascular disease, thyroid disease, peripheral neuropathy~* Drugs within 2 months : Digitalis, cimetidine, clofibrate, lithium, opiate, nifedipine, beta-agonist, beta-blocker, penicillamine, gabapentin, pregabalin, tricyclic anti-depressant, carbamazepine, phenytoin, quinidine, antispastic drugs, verapamil, vitamin E, branched chain amino acid, excessive alcohol consumption (male \>40 g/day, female \>20 g/day)~* Underlying disease : Renal impairment (Ccr \< 60 mL/min), neuromuscular disease (stroke, cerebral palsy, multiple sclerosis, Parkinson disease, progressive muscular dystrophy, epilepsy), suicidal attack, drug allergy, pregnancy, heart failure~* Liver status : Serious complications resulting from decompensated cirrhosis except ascites, such as portosystemic encephalopathy, acute variceal bleeding within the past 3 months from study entry~* central nervous system (CNS) or peripheral nervous system (PNS) or muscular disease, stroke, cerebral palsy, multiple sclerosis, Parkinson disease, progressive muscular dystrophy, epilepsy~* The previous episode of suicidal attack~* Drug hypersensitivity~* Subjects receiving antiepileptic drugs~* Patients manipulating machines or driving cars~* Pregnant women~* Subjects with congestive heart failure requiring medications~* Galactose-Lactose metabolic abnormality~* Refractory ascites to medical treatment

- Gender: ALL
- Minimum Age: None
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): 30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with pregabalin.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period.
- Placebo (Type: PLACEBO_COMPARATOR): 30 randomly allocated patients after a 4-week run-in period, who will take part in a 6-week treatment period with placebo.~Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as standard dose period + 75mg twice a day for a week as tapering period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Levobupivacaine With Opioids for Caesarean Section

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Pregnant women~* above 18 years of age~* gestational pregnancy age ≥ 36 weeks~* height ≥ 155 cm~* weight ≤110 kg~* fetal weight ≥ 2500 g)~* American Society of Anesthesiologists (ASA) Physical Status of I to II~* elective caesarean section surgeries were enrolled.~Exclusion Criteria:~* Local anesthetic allergy~* history of hypersensitivity and anaphylactic reactions~* emergency surgery~* preeclampsia

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: PLACEBO_COMPARATOR): Control Group, Group C: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ Serum saline
- Group Fentanyl (Type: ACTIVE_COMPARATOR): Group Fentanyl, Group F: Spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml+fentanyl (10 µg)
- Group sufentanil (Type: ACTIVE_COMPARATOR): Group sufentanil, Group S: spinal anesthesia with levobupivacaine %0.5 (2.2±0.2 ml)+ sufentanil (2.5 µg)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete